Register now for exclusive savings and additional group discounts: URLs: Tickets: Brochure: Prices: Drug Developer Pricing | Conference Only: USD 2999.00, Academic Pricing | Conference Only : USD 2599.00, Standard Pricing | Conference Only: USD 3699.00 Speakers: Andrew Young - Chief Medical Officer - i2o Therapeutics, Eduardo Santos - Executive Director and Head of General Medicines, Therapeutic Areas, and Business Development | Global Value, Access, and Pricing - Amgen, Feng Liu - Executive Director | Research and Development - Regor Therapeutics, Ibrahim Turfanda - Senior Director | Next Generation Incretins | NILEX and Outcomes - Eli Lilly, Jo Bednarik - Executive Director | Medical Development, Diabetes, and Obesity - Eli Lilly, Jonathan Douros - Associate Director | Biology and Pharmacology - Novo Nordisk, Lars Johansson - Chief Scientific Officer - Antaros Medical, Leilani Morales - Global Chapter Lead | Medical Development and Evidence Generation - Roche, Maggie Kelleher - Senior Director/Team Lead | Commercial Strategy and Innovation Business Assessment | Internal Medicine and Digital - Pfizer, Manu Chakravarthy - Chief Scientific and Medical Officer - Carmot Therapeutics, Matthew Coghlan - Vice President and Head Incretin Portfolio Science - Eli Lilly, Paul Rubin - Chief Medical Officer - BioAge Labs, Scott Harris - Chief Medical Officer - Altimmune, Seulki Lee - Chief Executive Officer | D and D Pharmatech, Todd Hobbs - Chief Medical Officer - Diasome Pharmaceuticals Have a Question About this Festival
PMID: 19110597
PMC 5178091
Imagine your experiment fails
[29] Similar reductions in fasting glucose were noted a 5% reduction in this study, [29] compared to a 5.8% reduction in the 200mg/day group from the previous study
Barati E, Nikzad H, Karimian M
